Abstract
Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors, serpins. It was first identified as a neuronal differentiating factor secreted by human retinal pigment epithelial cells, and then found to be the most potent inhibitor of pathological angiogenesis in mammalian eyes. Recently, PEDF has been shown not only to suppress oxidative stress and inflammatory reactions in vascular wall cells, T cells and macrophages, and adipocytes, but also to exert antithrombotic and anti-fibrotic properties, thereby protecting against the development and progression of various cardiometabolic diseases and related complications. Furthermore, accumulating evidence has suggested that circulating PEDF levels may be a biomarker of severity and prognosis of these devastating disorders. Number of subjects with visceral obesity and insulin resistance is increasing, and the metabolic syndrome and its related complications, such as diabetes, nonalcoholic fatty liver disease/non-alcoholic steatohepatits, and atherosclerotic cardiovascular disease are a growing health challenge. Therefore, in this study, we review the pathophysiological role of PEDF in obesity and metabolic disorders, cardiovascular disease, diabetic eye and kidney complications, liver diseases, and reproductive system disorders, and discuss the potential clinical utility of modulating the expression and actions of PEDF for preventing these cardiometabolic disorders. We also refer to the clinical value of PEDF as a biomarker in cardiometabolic complications.
Keywords: Cardiovascular disease, inflammation, metabolic disorder, oxidative stress, PEDF, retinopathy, diabetic nephropathy.
Current Medicinal Chemistry
Title:Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications
Volume: 25 Issue: 13
Author(s): Sho-ichi Yamagishi*Takanori Matsui
Affiliation:
- Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830-0011,Japan
Keywords: Cardiovascular disease, inflammation, metabolic disorder, oxidative stress, PEDF, retinopathy, diabetic nephropathy.
Abstract: Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors, serpins. It was first identified as a neuronal differentiating factor secreted by human retinal pigment epithelial cells, and then found to be the most potent inhibitor of pathological angiogenesis in mammalian eyes. Recently, PEDF has been shown not only to suppress oxidative stress and inflammatory reactions in vascular wall cells, T cells and macrophages, and adipocytes, but also to exert antithrombotic and anti-fibrotic properties, thereby protecting against the development and progression of various cardiometabolic diseases and related complications. Furthermore, accumulating evidence has suggested that circulating PEDF levels may be a biomarker of severity and prognosis of these devastating disorders. Number of subjects with visceral obesity and insulin resistance is increasing, and the metabolic syndrome and its related complications, such as diabetes, nonalcoholic fatty liver disease/non-alcoholic steatohepatits, and atherosclerotic cardiovascular disease are a growing health challenge. Therefore, in this study, we review the pathophysiological role of PEDF in obesity and metabolic disorders, cardiovascular disease, diabetic eye and kidney complications, liver diseases, and reproductive system disorders, and discuss the potential clinical utility of modulating the expression and actions of PEDF for preventing these cardiometabolic disorders. We also refer to the clinical value of PEDF as a biomarker in cardiometabolic complications.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi *, Matsui Takanori , Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications, Current Medicinal Chemistry 2018; 25 (13) . https://dx.doi.org/10.2174/0929867324666170608103140
DOI https://dx.doi.org/10.2174/0929867324666170608103140 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contrast-induced Nephropathy in Extra-cardiac Vascular Procedures – A Call to Action
Current Vascular Pharmacology Point-of-Care Testing in Diabetes Care
Mini-Reviews in Medicinal Chemistry Vasoactive Renal Factors and the Progression of Diabetic Nephropathy
Current Pharmaceutical Design Healing Effects of Curcumin Nanoparticles in Deep Tissue Injury Mouse Model
Current Drug Delivery Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Prediction and Diagnosis of Post Transplant Diabetes
Current Diabetes Reviews Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Actin-associated Proteins in the Pathogenesis of Podocyte Injury
Current Genomics Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Anemia in Patients with Diabetic Foot Ulcer: Effects on Diabetic Microvascular Complications and Related Conditions
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Advanced Glycation: Implications in Tissue Damage and Disease
Protein & Peptide Letters Selective Gene Amplification for High-Throughput Sequencing
Recent Patents on DNA & Gene Sequences Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Current Pharmaceutical Biotechnology Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: A Possible Role of Leptin
Current Pharmaceutical Design